17 March 2015: Diagnosis and drug delivery for diseases like cancer, cardiovascular and genetic ailments has always been a concern. In recent years, however, new strides and developments in the nano-medicine market have facilitated more effective diagnosis and drug delivery for diseases. Not only can these diseases now be studied better but it will also help us in making informed decisions producing better cures. The nano-medicine market is on a steady growth and with a compound annual growth rate (CAGR) of 12.5% from 2011; the market size will reach to $130.9 billion by 2016.
Nanotechnologies in Drug Delivery Congress organized by Markets and Markets Conferences is gathering industry experts from the nano-medicine market who will look at these developments and also present new ideas. Supported by the French Society for Nanomedicine, the congress will be held on 27 – 28 April 2015 in London, UK. Speaking at the congress will be AstraZeneca, Nemaura Pharma, Lloyds Register Quality Assurance, Cytoviva, World Nano Foundation, King’s College London, Institute for Biological and Medical Imaging, Uppsala University and University of Oxford among others.
One of the key speakers at the congress will be Prof. Andrew Owen, Professor of Molecular and Clinical Pharmacology at University of Liverpool and Chair at British Society for Nano medicine, Liverpool – UK. He will be delivering a special address on day one on nanotechnology – enabled drug delivery in HIV therapy. Prof. Owen holds a personal Chair in the Department of Molecular and Clinical Pharmacology at the University of Liverpool, UK and has contributed to over 120 original research and review publications, book chapters and patent applications.
Shedding light on the topic he said, “Nanotechnology-based HIV drug delivery has attracted recent attention within academia with many technologies in early stage evaluation for improving oral bioavailability or targeting HIV-infected cells and tissues. Interest has been significantly accelerated recently by the entry of long-acting Nano formulations into human trials. These Nano formulations developed by 17 March 2015: Janssen Pharmaceuticals and ViiV Healthcare are able to sustain therapeutic concentrations in blood for over 1 month from a single intramuscular depot injection.”
Prof. Owen believes nanotechnology – enabled drug delivery will positively influence future treatments of HIV patients. He stated, “Modern antiretroviral therapy has significantly improved morbidity and mortality but patient adherence to medication is an on-going issue that frequently results in treatment failure. Also, many antiretroviral drugs exhibit poor bioavailability and adverse drug reactions are common. The ability to administer drugs monthly rather than daily at lower overall doses may mitigate issues with adherence and pill fatigue, which will hopefully translate to improved patient outcomes.”
Other topics that will be covered at the congress include the role of nanomedicine and targeted medicine for personalised medicine, real-time, whole body, tracking of nanoparticle biodistribution using multispectral optoacoustic tomography, targeted nanomedicines in cancer therapy and combining diagnostics and delivery in a single device. The congress will be a great opportunity for delegates to learn about the new developments and also interact with global industry peers.